Triall is on a mission to streamline the development of new medicine using blockchain and Self-Sovereign Identity (SSI) technologies. We innovate on top of a platform that has been used by over 8,000 clinical trials globally. Powered by our utility token TRL, we are gradually building towards a data ecosystem that facilitates fair data exchange between researchers, patients, and the many other parties that contribute to clinical research.
TRL provides access to the Triall platform where it is used to purchase software and services for each new clinical trial.
65% of the TRL Platform Fee is locked for the entire duration of the clinical trial.
17.5% of the TRL Platform Fee is permanently burned from the token supply.
The remaining 17.5% is doubled with the reserves of the TRL Treasury and used to increase the liquidity depth of the TRL token market.
For patients and investigator communities. Promoting clinical trial recruitment, retention, and engagement—major issues in the current clinical trial environment.
Enabling fractional data ownership between Sponsor, CROs, Investigative Sites, and patients.
Direct, milestone-based payments and reimbursement, facilitated through programmable contracts and workflows.
Need help? We prepared several guides to help you on your way.
Last updated: Tue 01 Nov, 2022
World’s first to implement blockchain in live and running clinical trials with our successful pilot in 2019.
Deep understanding of industry needs and trends. Team managed 150+ clinical trials across 30+ countries.
Value network of industry partners and potential customers that stretches the globe.
Published blockchain article in Science and 250+ peer-reviewed papers on innovation in the Life Sciences.
Collaborating with industry-leading stakeholders in our customer domain to build our future vision.
The market for clinical trial software (‘eClinical solutions’) is growing at a CAGR of 13.8%.
Combined, our team has managed 150+ clinical trials across 30+ countries, published about clinical research and innovation in top-tier academic journals such as Nature Biotechnology and Science, and successfully developed companies through all stages of growth, both in the Life Sciences and in the enterprise software domain.Join Us
Head of Research, Public Health & Primary Care
Head of Integrated Data Analytics
VP Quality Assurance
Chief Medical Officer & Digital Health Entrepreneur
Full Professor & Sequential Biotech Entrepreneur
Associate Director Behavioral Science
Venture Capitalist & Innovation Advisor
We regularly publish articles about the Triall project on Medium. You may find a selection below.View all